Waterless Lotion and Lotion-Treated Substrate

ABSTRACT

A lotion includes a micro-emulsion composition, which is liquid at room temperature and undergoes a phase change to a semi-solid or solid upon contact with a substrate. The micro-emulsion composition can include a polar emollient, a non-polar emollient, a non-ionic surfactant, and a co-surfactant. The invention also includes a substrate treated with the lotion.

CLAIM OF PRIORITY

This application is a continuation of application U.S. Ser. No.10/141,442, filed on May 7, 2002. The disclosure of U.S. patentapplication Ser. No. 10/141,442 is hereby incorporated in its entiretyinto this application by reference thereto and priority thereof isclaimed.

FIELD OF THE INVENTION

The present invention relates to a waterless lotion and substratetreated with the waterless lotion. In particular, the present inventionrelates to a waterless micro-emulsion lotion which is liquid at roomtemperature and semi-solid upon contact with a substrate.

DESCRIPTION OF THE RELATED ART

Numerous examples of lotion formulae for bathroom tissue, facial tissueand non-woven material can be found in the art.

U.S. Pat. No. 5,607,760 to Roe relates to a lotion coating on the outersurface of the non-woven top sheet of an absorbent article, such asdiapers, pull-on products, adult incontinence devices, and the like. Thelotion composition is reported to convey a desirable therapeutic orprotective coating benefit and to be effective in reducing the adherenceof bowel movement to the skin. This waterless lotion is solid orsemi-solid at 20° C. and the most preferred melting point is ≧45° C. Bybeing semi-solid or solid at ambient temperature, the lotion does nothave a tendency to flow and migrate into the interior of the substrate.According to a process for the application of the lotion to a substrate,the lotion composition is placed in a heated tank operating at atemperature of 63° C., then sprayed onto the substrate by a spray headoperating at a temperature of 71° C.

U.S. Pat. No. 5,665,426 to Krzysik et al., discloses a lotion formulathat can be applied to a tissue which will remain readily available fortransfer to the user's skin to reduce skin irritation and redness. Thelotion composition includes from about 30 to about 90 weight per cent ofoil, from about 10 to about 40 weight per cent wax, and from about 5 toabout 40 weight percent fatty alcohol. The melting point of the lotioncomposition is from about 30° C. to about 70° C. The lotion was appliedto the tissue via a heated rotogravure printing process. Specifically,the formulation was pre-melted at about 56° C. and the press supplysystem (supply hose, doctor application head, and gravure roll) waspre-heated at about 50° C. The deposit solidified almost instantaneouslyon the surface of the treated tissue, dramatically increasing theproduct's hydrophobicity, and helping prevent “wet-through” to theuser's hand.

There is a need in the art to eliminate handling/application issuesassociated with “hot” lotion and improve the product softness andabsorbency of the lotion-treated substrate. In addition to providingthese advantages over “hot” lotion, uniformly, the present inventionprovides an easily applied, stable, substantially liquid lotion whichwhen applied to a cellulosic substrate results in a lotioned producthaving a lubricious, soothing, non-greasy feeling, gentle and effective,moisturizing benefit for the user's skin.

SUMMARY OF THE INVENTION

One aspect of the present invention includes a lotion including amicro-emulsion composition, which is substantially liquid at roomtemperature and undergoes a phase change to a semi-solid or solid uponcontact with a cellulosic substrate. The micro-emulsion compositionincludes a polar emollient, a non-polar emollient, a co-surfactant and anon-ionic surfactant.

Another aspect of the present invention includes a substrate treatedwith the lotion including a micro-emulsion composition, whichcomposition is liquid at room temperature and undergoes a phase changeto a semi-solid or solid upon contact with the cellulosic substrate.

Another aspect of the present invention includes a lotion including amicro-emulsion, which includes a polar emollient, a non-polar emollient,a non-ionic surfactant, and a co-surfactant wherein at least one of theemollients has substantial solubility in either cellulosic or syntheticfiber. Preferably, at least the polar emollient is soluble in cellulosicfibers and the non-polar emollient is more preferably soluble insynthetic fibers.

Another aspect of the present invention includes a lotion including: 35%polyalkoxy or polyhydroxy emollient; 12.5% aromatic ester, such as C₁₂to C₁₅ alkyl benzoate ester or mineral oil; 12.5% myristyl alcohol; and40% PEG-20 methyl glucose sesquistearate.

Additional features and advantages of the present invention will be setforth in the detailed description which follows, and in part will bereadily apparent to those skilled in the art from that description orrecognized by practicing the invention as described herein, includingthe claims, as well as the appended drawings.

It is to be understood that both the foregoing general description andthe following detailed description are merely exemplary of theinvention, and are intended to provide an overview or framework forunderstanding the nature and character of the invention as it isclaimed. The accompanying drawings are included to provide a furtherunderstanding of the invention, and are incorporated in and constitute apart of this specification. The drawings illustrate various embodimentsof the invention, and together with the description serve to explain theprinciples and operation of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a partial phase diagram of an embodiment of the presentinvention at room temperature showing the micro-emulsion region of thephase diagram.

FIG. 2 is a partial phase diagram of another embodiment of the presentinvention at room temperature showing the micro-emulsion region of thephase diagram.

FIG. 3 is a partial phase diagram of another embodiment of the presentinvention at room temperature showing the micro-emulsion region of thephase diagram.

FIG. 4 is a partial phase diagram of another embodiment of the presentinvention at room temperature showing the micro-emulsion region of thephase diagram.

FIG. 5 is a partial phase diagram of another embodiment of the presentinvention at room temperature showing the micro-emulsion region of thephase diagram.

FIG. 6 is a partial phase diagram of another embodiment of the presentinvention at room temperature showing the micro-emulsion region of thephase diagram.

FIG. 7 is a spectrum of the lotion residue transferred to a glassmicroscope slide after wiping with several lotioned substrates.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENT

The invention relates to a substrate treated with a waterlessmicro-emulsion lotion, which is liquid at room temperature. For thepurposes of the present invention, room temperature is a temperature offrom about 20° C. to about 25° C. The lotion formula of the presentinvention undergoes an in-situ phase change from liquid to semi-solid,finely divided, uniformly dispersed form upon contact with thesubstrate, for example, the fibers of the web. This property isimportant in preventing liquid lotion migration into the substrate orthe packaging, and in enhancing the lubricious, soft, and non-greasyfeeling of the lotioned substrate. Lotion in the substrate is readilytransferred to the user's skin by the friction from wiping and body heatto provide the benefits to the skin surface.

Furthermore, this lotion formula is also termed “cold” lotion since itis a liquid at room temperature. The term “hot” or “cold” lotion refersto either the lotion form being solid (“hot”) or liquid (“cold”) at roomtemperature and lotion application temperature either higher (“hot”) orat room temperature (“cold”). Application of a cold lotion does notrequire cumbersome and expensive heated delivery equipment. Rather, thelotion can be applied easily by any available technology such asspraying, printing, coating, extrusion or other techniques. Themicro-emulsion or “cold” lotion contains an external continuousnon-polar or polar emollient, an internal discontinuous polar ornon-polar emollient, a surfactant and a mixture of fatty alcoholco-surfactants. The lotion may also contain optional ingredients,including plant extracts, perfume and a medicinal agent.

The lotion of the present invention alleviates handling/applicationissues associated with a “hot” lotion and improves the product softnessand absorbency of the lotion treated substrate. This is achieved by thepresent waterless, hydrophilic, “cold” lotion, which is liquid at roomtemperature, that can be applied to the substrate without heatingequipment. The lotion is capable of an in-situ phase change from liquidto a semi-solid form upon contact with the web fibers which when loadedprevents lotion free flow and migration. In addition to these advantagesover a “hot” lotion, the lotioned product of the present invention alsoprovides a lubricious, soothing non-greasy feeling, gentle and effectivecleansing, skin healing and moisturizing benefit for the user's skin.Further, the lotion composition is able to incorporate typical cosmeticadditives, preservatives and anti-bacterial agents regardless of thewater solubility of the additive. Finally, facial tissue products madefrom “hot” lotion are usually not recommended for cleaning transparentmaterials, such as eyeglasses, due to the “hot” lotion leaving atranslucent or opaque smear. The present “cold” lotion treatedsubstrates do not suffer this deficiency.

The present invention relates to a substrate treated with a waterless,micro-emulsion lotion, which is liquid at room temperature. Thecomposition preferably includes four basic components: a polaremollient, non-polar emollient, co-surfactant, and non-ionic surfactant.

Preferred polar emollients include a polyhydroxy emollient. Preferredpolyhydroxy emollients include propylene glycol, glycol, glycerol,sorbitol, diethylene glycol, methylene glycol, poly propylene glycol,poly ethylene glycol, and the like.

Preferred non-polar emollients include an aromatic or linear ester,Guerbet ester, mineral oil, squalane, squalene, liquid paraffin and thelike.

The polar or non-polar emollient is either in the continuous outer phaseor in the discontinuous internal phase of the micro-emulsion.

Preferred co-surfactants include fatty alcohols. Preferred fattyalcohols include C₁₂ to C₁₈ fatty alcohols, behenyl alcohol, iso cetylalcohol, and iso stearyl alcohol.

Preferred non-ionic surfactants include PEG-20 methyl glucosesesquistearate, PPG-20 methyl glucose ether, PPG-20 methyl glucose etherdistearate, PEG-20 methyl glucose distearate, PEG-120 methyl glucosedioleate, ethoxylated methyl glucose having from about 10 to about 20repeating ethoxy units, and the like.

The compositions of the present invention are chosen to lie within themicro-emulsion region of a given formulation. All percentages, ratios,and proportions of the ingredients within the compositions of thepresent invention are determined by the micro-emulsion region of aternary phase diagram of the polar emollient/non-polaremollient/co-surfactant/non-ionic surfactant formulations(PE/NPE/COS/NIS). Outside of the micro-emulsion region on the lowpercent side of the polar or non-polar emollients, a semi-solid or solidregion is preferably present (see FIGS. 1-6). A micro-emulsion isthermodynamically stable and is essentially transparent in the visibleregion of the spectrum, which typically indicates that particle sizediameter is preferably less than about 0.1 micron or so. When theparticle size diameter is greater than about 3,200 A (about 0.32micron), the liquid is no longer considered a micro-emulsion but is anemulsion which can often appear turbid and be thermodynamicallyunstable. The micelle structure of a micro-emulsion is either a “direct”type (head out/tail in) or an “inverse” type (head in/tail out). Theliquid micro-emulsion increases the surface area of the lipophilicconstituent so it contributes significantly to the utility of thepresent composition in neat form. Fluidity on the skin surface, smallparticle size, high surface area and high hydrophilic character, arehighly desirable properties for cleansing purposes either when thesubstrate is used by itself or when lotioned products are rewet withwater. Any combination or proportion of these ingredients which producesa micro-emulsion can be used.

An important aspect of this invention is when the liquid lotion contactsthe fibers or non-woven substrate, it undergoes an in-situ phase changefrom liquid to semi-solid or solid form. This change results when thesubstrate web surface fibers absorb the continuous outer phase of themicro-emulsion. The continuous outer phase of the micro-emulsion may bea non-polar or polar-emollient. If it is a polar material, hydrogenbonding can be created between fibers and emollient. Therefore, thepercent of the outer phase of the micro-emulsion within the compositionis reduced, resulting in shifting the original lotion composition frompoint A (liquid) inside the micro-emulsion region, to point B or C(semi-solid) outside of the micro emulsion region (see FIGS. 1 to 6).This unique and special characteristic represents an advantage of theinvention, in contrast to the lotion of the prior art, in both processapplication and product performance.

In the application process, the lotion of the invention uses simple andlow cost technology relative to the prior art because it is waterlessand substantially liquid at room temperature. In contrast, most of thelotions used for treated tissue or non-woven substrate in the prior artare in semi-solid or solid form at room temperature, which requiresheated equipment to deliver lotion to the substrate. Furthermore, anydelivery technology available can be easily used for application of thelotion of the present invention without heating equipment, such as anair atomized spray coating, brush coater, curtain coater, and direct oroffset gravure coating. Cleaning the production line during or afterlotion application process due to build-up and solidification of lotionon the conveyer roll is also a serious issue with “hot” lotions. Thisissue is minimized with the present invention lotion; and in addition,at the converting line, the liquid lotion may act as a lubricant andimpede adhesion of “stickies” (gummy deposits from recycle fiberbasesheet) on the embossing rolls to improve the converting process andproduction rate.

The micro-emulsion is liquid at room temperature, but when in contactwith the paper or non-woven substrate, the lotion phase changes tosemi-solid form. This unique property provides for the liquid “cold”lotion advantages which are primarily associated with “hot” lotion suchas: (1) retaining more lotion on the substrate surface; (2) impedingpenetration of the lotion into the web without requiring an immobilizingagent; (3) reducing the amount of lotion applied required to enhance theproduct performances; and (4) reducing the impact of lotion on thephysical properties of the tissue. Additionally, if necessary, a higherlevel add-on of the present lotion can be applied to the substrate ascompared to the “hot” lotion due to the liquid form of the “cold” lotionat room temperature. In this case, the hydrophilic nature of the “cold”lotion product will remain resulting in better cleansing or enhancedskin care benefits, in contrast to the hydrophobic “hot” lotion. Thesecold lotions do not suffer from the common deviancy of hot lotionswherein it is observed that use of too much “hot” lotion can result inthe product becoming stiff.

The ability of the continuous outer phase to include either polar ornon-polar components provides advantages to the present invention. Bothpolar and non-polar emollients contribute to the ability of the presentinvention to accommodate a wide range of compatibility with variousadditives such as preservatives, anti-bacterial phase/agents, naturaltherapeutic oils, soothing agents, whether they are soluble or not inthe polar or non-polar emollient. In other words, the formulations ofthe present invention may be designed to be effective at promotingnumerous consumer benefits. For example, in a wiper product containing ahigh add-on level (100% to 300%) of the present lotion for cleansingoil-based dirt or grease on the skin, the preferred lotion compositionincludes a polar emollient outer phase/ non polar oil internal phase/hydrophilic surfactant with co-surfactant fatty alcohol C₁₄ to C₁₈.After application of the micro-emulsion to the cellulosic substrate, theweight percent of the outer phase polar emollient is preferably very lowrelative to the non-polar internal phase emollient as the polar phase isstrongly absorbed by the cellulosic fibers. In wiping oily skinsurfaces, the product releases the non-polar emollient (as a carrier)and the nonionic surfactant. This combination emulsifies the oil-baseddirt or grease on the skin and, by encapsulating it inside the micellestructure after wiping, carries it into the internal phase of thecleaning formulation without leaving a non-polar oil phase on the skin.This formulation is well-suited for cleaning of oils. We prefer that theouter phase be polar because the grease or oil goes into the non-polarphase on the wipe and thus may be removed. This micro-emulsion with apolar outer phase is believed better for cleansing oil from the skinsurface than using a lotion formulation of non-polar oil emollient outerphase/polar emollient internal phase/nonionic surfactant plusco-surfactant because lotions having a non-polar continuous phasemicelle structure contacts the skin with the oily phase, thus thenon-polar outer phase only dissolves the contaminant and, thus, canleave both the oil-based contaminant and non-polar oil phase on the skinsurface. Thus a product treated with formulations having continuousnon-polar phases are less desirable for removal of oils or greasymaterial because non-polar liquid is often left on the skin afterwiping.

Conventional liquid lotions for a tissue substrate (oil-in-wateremulsion) are well known in the art, but generally have at least 70-80%water in the formula. Water in the lotion formula is undesirable forpost treatment of the tissue product because: (1) it limits the amountof lotion that can be applied to the substrate due to the lotion havinga low percent solid; (2) the large negative impact on the product'sphysical properties and problems encountered at the treatment line dueto water rewetting and weakening of the paper; and (3) the need toinstall an oven, or other drying device, on the treatment line forremoval of the water in the substrate. The present invention formula iswaterless but still maintains the ability of incorporating water-solubleadditives into the polar phase, plus easily adding oil soluble additivesinto the non-polar phase of the lotion. This capability is also anadvantage of the “cold” lotion compared to “hot” lotion. Incorporatingwater-based additives in “hot” lotion is very difficult, due to phaseseparation and loss of uniform distribution of the additive in thelotion, either before or after application onto the product substrate.Water content in “hot” lotion of up to 10 or 15 percent might eliminatethe phase separation problem, but controlling and maintaining watercontent in a lotion formulation at high temperature (about 75° C. toabout 90° C.) during process application can be a difficult task. Thisdisadvantage is avoided by the “cold” lotion of the present invention.

The invention relates to a tissue, towel or napkin, optionallywet-strengthened, or wipe or nonwoven material, such as that used fordiaper, incontinence and menstrual pad coverstock that is treated with anongreasy-feeling lotion. The lotion has the effect of making thetreated substrate feel nongreasy, reducing chaffing and irritation whenthe substrate is applied to the skin, and imparting a lubricious feel.Skin care benefits of the lotionized substrate are expressed whether theinvention is used dry or prewetted with water.

The lotion can optionally include a therapeutic amount of a medicinalagent. Medicinal agents include medicines, antipathogenic agents,antimicrobial agents, antibacterial agents, antiviral agents,disinfectants, analgesics, other types of medicine having suitablemedicinal properties, and the like. For example, an antibacterial agentcan be present in an amount of from about 0.01% to about 10%, preferablyfrom about 0.05% to about 5%, of the lotion. Suitable antimicrobialagents include those effective against human pathogens, such asescherichia coli staphylococcus aureus, salmonella chloreraesuis,salmonella typhi, pseudomonas aeruginosa, pseudomonas cepacia, and thecandida species, including albicans. Specific antimicrobial agentssuitable for use in the lotion of the invention include2,4,4′-trichloro-2′-hydroxydiphenyl ether (triclosan);3,4,4′-trichlorocarbanilide (triclocarban);3,4,4′-trifluoromethyl-4,4′-dichlorocarbanilide (cloflucarban);5-chloro-2-methyl-4-isothiazolin-3-one; iodopropynlbutylcarbamate;8-hydroxyquinoline; 8-hydroxyquinoline citrate; 8-hydroxyquinolinesulfate; 4-chloro-3,5-xylenol(chloroxylenol);2-bromo-2-nitropropane-1,3-diol; diazolidinyl urea; butoconazole;nystatin; terconazole; nitrofurantoin; phenazopyridine; acyclovir;clortrimazole; chloroxylenol; chlorhexidine; chlorhexidine gluconate;miconazole; terconazole; butylparaben; ethylparaben; methylparaben;methylchloroisothiazoline; methylisothiazoline; a mixture of1,3-bis(hydroxymethyl)-5,5-dimethylhydantoin and 3-iodo-2-propynyl butylcarbamate; oxyquinoline; EDTA; tetrasodium EDTA; p-hydroxyl benzoic acidester; alkyl pyridinum compounds; quaternary ammonium compounds, such ascoco phosphatidyl PG-dimonium chloride; mixtures thereof; and the like.Other preferred antimicrobial agents include derivatives of substitutedN-alkyl imidazolines disclosed in U.S. Pat. No. 4,078,071 to Walker,issued Mar. 7, 1978, which is incorporated hereby in reference in itsentirety.

An anti-viral agent can be present in an amount of from about 0.025% toabout 5%, preferably from about 0.05% to about 2.5%, of the lotion.Suitable anti-viral agents include those effective against, or at leastretardant toward Corona virus, Picorna virus, Rhino virus, Herpessimplex, Herpes genitalis, Herpes labialis, Respiratory Syncytial Virus(RSV), Para influenza, Cytomegalovirus, Adenovirus, Condyloma andcertain synergistic disease states that can involve a virus and aprotozoa or a virus and any unfriendly enzymes, e.g., protease, lipaseand amylase, that cause a compromised skin as a precursor state for aviral infection to occur. Specific anti-viral agents suitable for use inthe lotion of the present invention include bioflavonoids such ashesperitin, naringin, catechin and certain selected amino acids ofleguminous origin such as L-canavanine and an analog of L-arginine;dicarboxylic acids such as malonic, glutaric, citric, succinic, anddiglycolic acids; alpha hydroxy carboxylic acid such as D-galacturonicacid from Sterculia urens; neem seed oil (Azadirachta indica) in itsun-denatured form; sandalwood oil (Santalum album L.) in itsun-denatured form. Optionally, the anti-viral agent could be admixedwith at most about 50% by weight of the anti-viral agent of a proteaseinhibitor such as zinc oxide or other suitable zinc salt.

The lotion can optionally include fragrance. The fragrance can bepresent in an amount of from 0.01% to about 2%. Suitable fragranceincludes volatile aromatic esters, non-aromatic esters, aromaticaldehydes, non-aromatic aldehydes, aromatic alcohols, non-aromaticalcohols, heterocyclic aroma chemicals, and natural floral fragrances,such as blossom, carnation, gardenia, geranium, iris, hawthorne,hyacinth and jasmine.

The lotion can optionally include natural or synthetic powder like talc,mica, boron nitride, silicone, or mixtures thereof.

The substrate web of the present invention optionally includes a wetstrength agent. The wet strength agent includes temporary as well aspermanent wet strength agents. Suitable wet strength agents includeglyoxal; glutaraldehyde; uncharged chemical moieties selected from agroup consisting of dialdehydes, aldehyde-containing polyols, unchargedaldehyde-containing polymers, and cyclic ureas and mixtures thereof, andaldehyde-containing cationic starch; mixtures of polyvinyl alcohol andsalts of multivalent anions, such as boric acid or zirconium ammoniumcarbonates; glyoxalated polyacrylamide; polyamide-epichlorohydrin;polyamine-epichlorohydrin; urea-formaldehyde; melamine-formaldehyde;polyethyleneimine; and latex emulsions.

The lotion composition can include other optional components typicallypresent in lotions of this type. These optional components include abotanical extract, such as aloe extract, avocado oil, basil extract,sesame oil, olive oil, jojoba oil, chamomile extract, eucalyptusextract, peppermint extract, as well as animal oils such as emu oil, codliver oil, orange roughy oil, mink oil, and the like. The lotion of thepresent invention can also optionally include a humectant. Humectantsare hygroscopic materials with a two-fold moisturizing action includingwater retention and water absorption. Humectants prevent the loss ofmoisture from skin and help to attract moisture from the environment.Preferred humectants include glycerol, hydrolyzed silk, ammoniumlactate, hydroxypropyltrimonium hydrolyzed silk, hydroxypropyl chitosan,hydroxypropyltrimonium hydrolyzed wheat protein,lactamidopropyltrimonium chloride, and ethyl ester of hydrolyzed silk.The botanical extract, animal oil or humectant is preferably present inan amount of less than about 3% when used in the base formulation of thelotion. Further optional components include a skin refreshing agent suchas encapsulated water in oil, eucalyptus oil, and menthol oil. All ofthese optional materials are well known in the art as additives for suchformulations and can be employed in appropriate amounts in the lotioncompositions of the present invention by those skilled in the art.

The substrate of the present invention can be any suitable applicatorthat the lotion can be retained upon. Suitable substrates include a web,gauze, cotton swab, transdermal patch, container or holder. The lotionmay be retained on the substrate in any convenient amount.

The web of the present invention can be any suitable substrate web,including a flushable or nonflushable web of cellulosic fibers; a web ofsynthetic fibrous material; tissue, towel or napkin, optionallywet-strengthened; wipe or nonwoven material, such as that used fordiaper, incontinence and menstrual pad cover-stock; and the like.Suitable synthetic fibrous material includes meltblown polyethylene,polypropylene, copolymers of polyethylene and polypropylene, bicomponentfibers including polyethylene or polypropylene, and the like. Thesubstrate also may be embossed.

The present invention includes a flushable or nonflushable web ofcellulosic fibers treated on at least one side thereof, preferably in anamount of from about 0.1% to about 25%, more preferably from about 0.5%to about 20%, by weight of the dried fiber web with the lotion of thepresent invention. The present invention further relates to a web ofsynthetic fibrous material treated on at least one side thereof,preferably in an amount of from about 0.1% to about 25%, more preferablyfrom about 0.5% to about 20%, by weight of the dried web with the lotionof the present invention.

The substrate can be prepared according to conventional processes(including TAD, CWP and variants thereof) known to those skilled in theart. The substrate may be creped or uncreped. Lotion can be applied tothe substrate according to conventional application methods known tothose skilled in the art.

EXAMPLES

Formulations of the substantially waterless micro-emulsion of thisinvention were prepared in which, the components, their ratios and theconditions selected to provide micro-emulsion subject to in-situ phasechange upon contact with a cellulosic substrate were varied as shown inthe following Examples.

In preparing each formulation the following general procedure was used.The polar phase propylene glycol was mixed with surfactant andco-surfactant in a heated container at about 60° C. to about 70° C.until the chemicals are completely melted. The non-polar oil phase isadded to the mixture with moderate agitation for about 10 minutes, thencooled to room temperature. At this point the lotion is in clear liquidform and ready to apply to the substrate. The micro-emulsion formsspontaneously without the need for a high shear mechanical device and isstable indefinitely.

Examples 1-7

Examples 1 to 7 were prepared in accordance with the present invention.These lotion formulas are liquid at room temperature, transparent, verystable and accordingly the lotion ingredient ratios are inside themicro-emulsion region of the phase diagrams from FIG. 1 (Example 1),FIG. 2 (Example 2), FIG. 3 (Example 3), FIG. 4 (Example 4), FIG. 5(Examples 5 and 6). Surprisingly, the lotion of the present invention ischaracterized as having a good hand-feel perception and non-greasyhand-feel, which is thought to be due to the particle size of themicro-emulsion being too small to be detected in the oil phase by thefingertips. TABLE 1 Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 5 Ex. 6 Ex. 7Ingredients (%) (%) (%) (%) (%) (%) (%) Propylene glycol 35 35 5 15 1530 35 Finsolv TN⁽¹⁾ 12.5 0 16 0 30 15 0 Carnation Oil⁽²⁾ 0 0 0 0 0 012.5 Isopropyl myristate 0 15 0 30 0 0 0 Lambert CE 2000⁽³⁾ 0 0 4 0 0 00 Myristyl alcohol (C₁₄) 12.5 15 0 0 0 0 12.5 Kalcol 1618⁽⁴⁾ 0 0 7.5 05.5 5.5 0 Glucam P-20 0 0 67.5 0 49.5 49.5 0 Distearate⁽⁵⁾ GlucamateSSE-20⁽⁶⁾ 40 35 0 55 0 0 40⁽¹⁾Finsolv TN: C₁₂ to C₁₅ alkyl benzoate ester from Finetex Inc.⁽²⁾Carnation: Mineral oil from Witco Corp.⁽³⁾Lambert CE 2000: tri-octyldodecyl-citrate (Guerbet ester) fromLambent Technologies.⁽⁴⁾Kalcol 1618: Mixture 50/50 of cetyl alcohol (C₁₆) and stearyl alcohol(C₁₈) from Kao Corp.⁽⁵⁾Glucam P-20 Distearate: PEG-20 methyl glucose distearate fromAmerchol.⁽⁶⁾Glucamate SSE-20: PEG-20 methyl glucose sesquistearate from Amerchol.

Example 8

The lotion prepared in Example 1 was applied to a tissue basesheet at a5% add-on level, then converted to a two ply tissue product. The productwas tested for the amount of lotion transferred to the skin. The resultswere compared with commercially available lotioned tissues by comparingthe light reflection of cold lotion residual on glass relative to thatfrom two other products. The scattering of light caused by lotionsmeared onto the glass microscope slide is measured by using theUV/visible spectrophotometer in the wavelength region from 700 nm to 400nm. Lotion was transferred to the slide by holding it between two layersof lotioned tissue for 30 seconds and then rubbing the tissue over theslide 20 times in 15 seconds. The lotion smeared glass slide was placedin the sample beam of a double beam UV/Visible spectrometer to measurethe light scattering. The results in FIG. 7 show that scattering oflight caused by lotion smeared onto the slide rubbed with the tissuetreated with the lotion in Example 1, looked identical to the control(untreated tissue). However, the two commercially available lotionedfacial tissue products tested produced a significant amount of lightscattering compared to the lotioned tissue of the present invention. Infact, the containers for these commercial products specifically state“not recommended for cleaning eyeglasses.” In addition, from the labtest result, the amount of lotion transferred by the lotioned substrateof the present invention to the skin is measured to be about 4.2 mg/cm².

The lotioned substrate product of the present invention is able totransfer lotion to the skin for enhancing skin care benefits, while alsobeing able to “wipe eyeglasses and still maintain clear vision.” Theseproperties of the present invention represent significant advantagesover the lotioned facial tissues of the prior art.

Examples 9 and 10

The lotion treated substrate web of the present invention optionallyincludes a wet strength agent. The wet strength agent includes permanentas well as temporary wet strength. Example 10 illustrates crossdirectional wet tensile decay versus soaking time of the presentinvention basesheet treated with temporary wet strength agentglyoxalated poly(acryamide-co-DADMAC) with 5% of the lotion ofExample 1. The cross directional wet tensile (CD wet tensile) ismeasured by the Finch Cup Test method. TABLE 2 Example 9 Example 10Control Treated Product (without lotion) (with lotion) CD Wet (%) Wet CDWet (%) Wet Times Tensile CD Lost Tensile CD Lost (minutes) (G/3″) (%)(G/3″) (%) 0 47 — 40.5 — 1 40 15% 35 14% 2 36 23% 32 21% 4 32 32% 25 38%8 30 36% 25 38%

The data in Table 2 indicates that after 4 minutes of soaking in tapwater, the percent CD wet tensile lost of the present invention (Example10) is greater than the control without lotion (Example 9). This is asurprising property of the present invention because a tissue producttreated with the hot lotion of the prior art usually tends to reduce theproduct's hydrophilic properties, therefore, the break up times or thesinking times in tap water is usually increased. This feature of thepresent invention is important for preventing the clogging of toiletsand septic systems, while maintaining a desireable initial wet strengthlevel during use.

1. A wet-laid cellulosic tissue, said tissue bearing a microemulsioncomposition comprising an antiviral compound, said microemulsioncomposition being liquid at room temperature and undergoing a phasechange to a semi-solid or solid upon contact with said wet-laidcellulosic tissue, said antiviral compound being chosen from the groupconsisting of: bioflavonoids; dicarboxylic acids; alpha hydroxycarboxylic acids; neem seed oil; sandalwood oil; protease inhibitors andmixtures thereof.
 2. The wet-laid cellulosic tissue of claim 1, whereinsaid antiviral compound is chosen from the group consisting of:hesperitin; naringin, catechin, L-canavanine and analogues ofL-arginine; dicarboxylic acids; alpha hydroxy carboxylic acids; neemseed oil; sandalwood oil; protease inhibitors and mixtures thereof. 3.The wet-laid cellulosic tissue of claim 1, wherein said antiviralcompound is chosen from the group consisting of: bioflavonoids; malonicacid; glutaric acid, citric acid, succinic acid, diglycolic acid, alphahydroxy carboxylic acids; neem seed oil; sandalwood oil; proteaseinhibitors and mixtures thereof.
 4. The wet-laid cellulosic tissue ofclaim 1, wherein said antiviral compound is chosen from the groupconsisting of: bioflavanoids; dicarboxylic acids; D-galacturonic acid;neem seed oil; sandalwood oil; protease inhibitors and mixtures thereof.5. The wet-laid cellulosic tissue of claim 1, wherein said antiviralcompound is chosen from the group consisting of: bioflavonoids;dicarboxylic acids; alpha hydroxy carboxylic acids; neem seed oil;sandalwood oil; zinc oxide and mixtures thereof.
 6. The wet-laidcellulosic tissue of claim 1, wherein said antiviral compound is chosenfrom the group consisting of: hesperitin; naringin, catechin,L-canavanine and analogues of L-arginine; malonic acid; glutaric acid,citric acid, succinic acid, diglycolic acid; D-galacturonic acid; neemseed oil; sandalwood oil; zinc oxide and mixtures thereof.
 7. A sheet oflotioned tissue comprising a wet laid cellulosic substrate formed by theprocess of providing: said wet-laid cellulosic substrate, applying alotion having micro-emulsion phase to said wet-laid cellulosic substratein the amount of between about 0.1% and 25% by weight of the driedcellulosic substrate, the composition of said lotion upon applicationlying in the micro-emulsion phase and being liquid at room temperatureand undergoing a phase change to a semi-solid or solid upon contact withsaid wet-laid cellulosic substrate, said lotion comprising a polaremollient; a non-polar emollient, a fatty alcohol and a non-ionicsurfactant, said lotion being in finely divided, semi-solid formdispersed upon the fibers of the wet-laid cellulosic substrate.
 8. Thesheet of lotioned tissue of claim 7, wherein said lotion in saidmicro-emulsion phase is essentially transparent in the visible region ofthe spectrum.
 9. The sheet of lotioned tissue of claim 7 wherein thesize of the dispersed phase in the micro-emulsion phase of said lotionis less than about 0.1 μm in diameter.
 10. The sheet of lotioned tissueof claim 7, wherein said micro-emulsion phase comprises a continuoushydrophilic outer phase.
 11. The sheet of lotioned tissue of claim 7wherein said lotion is essentially waterless.
 12. The sheet of lotionedtissue of claim 7 wherein the micro-emulsion phase of said lotion has anadjoining semi-solid phase reachable by removal of polar emollient fromthe micro-emulsion phase.
 13. The sheet of lotioned tissue of claim 7wherein said wet-laid cellulosic substrate is a TAD web.
 14. The sheetof lotioned tissue of claim 7 wherein said wet-laid cellulosic substrateis a CWP web.
 15. A sheet of lotioned tissue comprising a wet laidcellulosic substrate exhibiting temporary wet strength formed by theprocess of providing said wet-laid cellulosic substrate, applying alotion having a micro-emulsion phase to said wet-laid cellulosicsubstrate in the amount of between about 0.1% and 25% by weight of thedried cellulosic substrate, the composition of said lotion uponapplication lying in the micro-emulsion phase and being liquid at roomtemperature and undergoing a phase change to a semi-solid or solid uponcontact with said wet-laid cellulosic substrate, said lotion comprisinga polar emollient; a non-polar emollient, a fatty alcohol and anon-ionic surfactant, said lotion being in finely divided, semi-solidform dispersed upon the fibers of the wet-laid cellulosic substrate. 16.The sheet of lotioned tissue of claim 15 wherein, upon immersion inwater, the temporary wet strength of said lotioned tissue decays morerapidly during an initial period of time than does an equivalentnon-lotioned sheet comprising the same temporary wet strength andexhibiting substantially equivalent initial wet strength.
 17. The sheetof lotioned tissue of claim 16 wherein the wet strength of the lotionedproduct decays more rapidly on a percentage of initial wet strengthbasis than does the equivalent non-lotioned sheet.
 18. The sheet oflotioned tissue of claim 16 wherein the wet strength of the lotionedproduct decays more rapidly on an absolute basis than does theequivalent non-lotioned sheet.
 19. The sheet of lotioned tissue of claim15 wherein the amount of lotion applied is between about 0.5% and 20% ofthe weight of the cellulosic substrate based on the dry weight of thesubstrate.
 20. The sheet of lotioned tissue of claim 15 wherein initialwet strength of the lotioned tissue is at least about 40 g/3″ asmeasured by the Finch cup method.
 21. The sheet of lotioned tissue ofclaim 20 wherein the wet strength of said lotioned tissue is no morethan about 25 g/3″ when measured by the Finch cup method 4 minutes afterimmersion.
 22. The sheet of lotioned tissue of claim 20 wherein the wetstrength of said lotioned tissue is no more than about 6% of the initialwet strength when measured by the Finch cup method 4 minutes afterimmersion.